Fig. 4: Antibody response in hematological patients and HCP.

A Index of IgM, IgG, and IgA antibodies against the receptor-binding domain (RBD) of the S-glycoprotein in health care practitioners (HCP, N = 102) and hematological patients (N = 83). B Concentration of anti-RBD IgG in HCP, hematological patients with B-cell lymphoproliferative disorders (B-cell dis., N = 48), monoclonal gammopathies (MG, N = 28) and Hodgkin lymphoma (HL, N = 7). C Concentration of anti-RBD IgG in HCP, hematological patients that had never received treatment (No Tx, N = 17), those that were on (N = 17), and patients that were off-treatment (N = 49) before vaccination. D Concentration of anti-RBD IgG in HCP and hematological patients with or without previous SARS-CoV-2 infection, based on the detection of IgG antibodies against the nucleocapsid (N) protein and the main virus protease (Mpro). Among HCP, 85 were negative and 17 positive for both antigens. Among hematological patients, 70 were negative and 13 positive for both antigens. In all panels, horizontal lines represent the median. *P < 0.05; **P < 0.01; ***P < 0.001.